- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
New potential treatment pathway against diffuse large large B-cell lymphoma
Researchers from Weill Cornell Medical College believe they have discovered a new pathway for treatment of patients with diffuse large B-cell lymphoma (DLBCL), the most commonly diagnosed subtype of non-Hodgkin's lymphoma.
Current standard treatment for DLBCL includes combination chemotherapy in the form of R-CHOP followed by radiation, but this treatment carries a significant toxicity profile along with tissue damage and sometimes severe side effects. A more targeted treatment is therefore in order.
Patients with DLBCL often have tumors that express the BLC-6 gene mutation, offering these researchers a potential treatment pathway by using an inhibitor known as RI-BPI along with a histone deacetylases (HDAC) inhibitor or with a heat shock protein (Hsp90) inhibitor. When researchers exploited this pathway, they were able to stifle tumor activity and even wipe out any signs of cancer.
NOTE: These results are derived from pre-clinical (mouse model) trials and should therefore be considered accordingly.
WHERE WAS THIS STUDY PUBLISHED?
Journal of Clinical Investigation